Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 15/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26946029 | 0.87 | KDM4E (0.38) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL24359900 | 0.83 | KDM4E (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL11330585 | 0.83 | KDM4E (0.53) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL20122458 | 0.81 | ACE (0.47) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL20122461 | 0.80 | KDM4E (0.55) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL9324856 | 0.78 | KDM4E (0.61) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6661780 | 0.78 | KDM4E (0.61) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL6661779 | 0.78 | KDM4E (0.61) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL24668415 | 0.77 | KDM4E (0.55) | ACEKDM4EMAPTTHRBALOX15 | |
| Bucillamine SCHEMBL5060887 | 0.77 | MAPT (0.59) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | ACE 487/4885KDM4E 3937/4885MAPT 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.